AR111200A1 - THIOCARBAMATE DERIVATIVES AS A2A INHIBITORS AND METHODS FOR USE IN CANCER TREATMENT - Google Patents

THIOCARBAMATE DERIVATIVES AS A2A INHIBITORS AND METHODS FOR USE IN CANCER TREATMENT

Info

Publication number
AR111200A1
AR111200A1 ARP180100778A ARP180100778A AR111200A1 AR 111200 A1 AR111200 A1 AR 111200A1 AR P180100778 A ARP180100778 A AR P180100778A AR P180100778 A ARP180100778 A AR P180100778A AR 111200 A1 AR111200 A1 AR 111200A1
Authority
AR
Argentina
Prior art keywords
alkyl
aminocarbonyl
amino
heteroaryl
membered
Prior art date
Application number
ARP180100778A
Other languages
Spanish (es)
Original Assignee
Iteos Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iteos Therapeutics filed Critical Iteos Therapeutics
Priority to DK18716193.0T priority Critical patent/DK3601296T3/en
Priority to TW112113401A priority patent/TWI836960B/en
Priority to MX2019011743A priority patent/MX2019011743A/en
Priority to KR1020247005971A priority patent/KR20240027885A/en
Priority to IL300149A priority patent/IL300149A/en
Priority to CA3058260A priority patent/CA3058260A1/en
Priority to SI201830747T priority patent/SI3601296T1/en
Priority to CN202211658370.5A priority patent/CN115991679A/en
Priority to AU2018246355A priority patent/AU2018246355B2/en
Priority to EP22165965.9A priority patent/EP4112623A1/en
Priority to KR1020197031322A priority patent/KR102640927B1/en
Priority to JP2020503355A priority patent/JP7197558B2/en
Priority to HUE18716193A priority patent/HUE059990T2/en
Priority to HRP20221039TT priority patent/HRP20221039T1/en
Priority to BR112019020421A priority patent/BR112019020421A8/en
Priority to RS20220794A priority patent/RS63557B1/en
Priority to PL18716193.0T priority patent/PL3601296T3/en
Priority to CN202211706953.0A priority patent/CN115873022A/en
Priority to CN201880034926.9A priority patent/CN110678472B/en
Priority to TW107111155A priority patent/TWI801372B/en
Priority to PCT/EP2018/058301 priority patent/WO2018178338A1/en
Priority to ES18716193T priority patent/ES2926158T3/en
Priority to EP18716193.0A priority patent/EP3601296B1/en
Priority to RU2019134724A priority patent/RU2822758C2/en
Priority to LTEPPCT/EP2018/058301T priority patent/LT3601296T/en
Priority to US16/354,022 priority patent/US10995101B2/en
Publication of AR111200A1 publication Critical patent/AR111200A1/en
Priority to IL269710A priority patent/IL269710B2/en
Priority to MX2022005298A priority patent/MX2022005298A/en
Priority to US16/993,897 priority patent/US20210198281A1/en
Priority to US17/949,595 priority patent/US20230159564A1/en
Priority to JP2022199962A priority patent/JP2023027282A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D497/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto de la fórmula (1), o una de sus sales o solvatos farmacéuticamente aceptables, en donde: R¹ representa heteroarilo de 5 ó 6 miembros o arilo de 5 ó 6 miembros, en donde los grupos heteroarilo o arilo están opcionalmente sustituidos con uno o varios sustituyentes seleccionados de alquilo C₁₋₆ (con preferencia, metilo) y halo (con preferencia, fluoro o cloro); con preferencia, R¹ representa heteroarilo de 5 miembros; con mayor preferencia, R¹ representa furilo; R² representa arilo de 6 miembros o heteroarilo de 6 miembros, en donde los grupos heteroarilo o arilo están opcionalmente sustituidos con uno o varios sustituyentes seleccionados de halo, alquilo, heterociclilo, alcoxi, cicloalquiloxi, heterocicliloxi, carbonilo, alquilcarbonilo, aminocarbonilo, hidroxicarbonilo, heterociclilcarbonilo, alquilsulfóxido, alquilsulfonilo, aminosulfonilo, heterociclilsulfonilo, alquilsulfonimidoilo, carbonilamino, sulfonilamino y alquilsulfonalquilo; donde dichos sustituyentes están opcionalmente sustituidos con uno o varios sustituyentes seleccionados de oxo, halo, hidroxi, ciano, alquilo, alquenilo, aldehído, heterociclilalquilo, hidroxialquilo, dihidroxialquilo, hidroxialquilaminoalquilo, aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo, (heterociclil)(alquil)aminoalquilo, heterociclilo, heteroarilo, alquilheteroarilo alquino, alcoxi, amino, dialquilamino, aminoalquilcarbonilamino, aminocarbonilalquilamino, (aminocarbonilalquil)(alquil)amino, alquenilcarbonilamino, hidroxicarbonilo, alquiloxicarbonilo, aminocarbonilo, aminoalquilaminocarbonilo, alquilaminoalquilaminocarbonilo, dialquilaminoalquilaminocarbonilo, heterociclilalquilaminocarbonilo, (alquilaminoalquil)(alquil)aminocarbonilo, alquilaminoalquilcarbonilo, dialquilaminoalquilcarbonilo, heterociclilcarbonilo, alquenilcarbonilo, alquinilcarbonilo, alquilsulfóxido, alquilsulfoxidoalquilo, alquilsulfonilo y alquilsulfonalquilo; o los grupos heteroarilo o arilo están opcionalmente sustituidos con dos sustituyentes que forman, junto con los átomos a los que están unidos, un anillo de arilo de 5 ó 6 miembros, un anillo heteroarilo de 5 ó 6 miembros, un anillo cicloalquilo de 5 ó 6 miembros o un anillo heterociclilo de 5 ó 6 miembros; opcionalmente sustituido con uno o varios sustituyentes seleccionados de oxo, halo, hidroxi, ciano, alquilo, alquenilo, aldehído, heterociclilalquilo, hidroxialquilo, dihidroxialquilo, hidroxialquilaminoalquilo, aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo, (heterociclil)(alquil)aminoalquilo, heterociclilo, heteroarilo, alquilheteroarilo, alquino, alcoxi, amino, dialquilamino, aminoalquilcarbonilamino, aminocarbonilalquilamino, (aminocarbonilalquil)(alquil)amino, alquenilcarbonilamino, hidroxicarbonilo, alquiloxicarbonilo, aminocarbonilo, aminoalquilaminocarbonilo, alquilaminoalquilaminocarbonilo, dialquilaminoalquilaminocarbonilo, heterociclilalquilaminocarbonilo, (alquilaminoalquil)(alquil)aminocarbonilo, alquilaminoalquilcarbonilo, dialquilaminoalquilcarbonilo, heterociclilcarbonilo, alquenilcarbonilo, alquinilcarbonilo, alquilsulfóxido, alquilsulfoxidoalquilo, alquilsulfonilo y alquilsulfonalquilo.Claim 1: A compound of the formula (1), or a pharmaceutically acceptable salt or solvate thereof, wherein: R¹ represents 5 or 6 membered heteroaryl or 5 or 6 membered aryl, wherein the heteroaryl or aryl groups are optionally substituted with one or more substituents selected from C₁₋₆ alkyl (preferably, methyl) and halo (preferably, fluoro or chloro); preferably, R¹ represents 5-membered heteroaryl; more preferably, R¹ represents furyl; R² represents 6-membered aryl or 6-membered heteroaryl, wherein the heteroaryl or aryl groups are optionally substituted with one or more substituents selected from halo, alkyl, heterocyclyl, alkoxy, cycloalkyloxy, heterocyclyloxy, carbonyl, alkylcarbonyl, aminocarbonyl, hydroxycarbonyl, heterocyclylcarbonyl , alkylsulfoxide, alkylsulfonyl, aminosulfonyl, heterocyclylsulfonyl, alkylsulfonimidoyl, carbonylamino, sulfonylamino and alkylsulfonalkyl; wherein said substituents are optionally substituted with one or more substituents selected from oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl) amino (heterocyclyl) amino , heteroaryl, alkyne alkylheteroaryl, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonyl) (alkyl) amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalquilaminocarbonilo, alquilaminoalquilaminocarbonilo, dialquilaminoalquilaminocarbonilo, heterociclilalquilaminocarbonilo, (alkylaminoalkyl) (alkyl) aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl and alkylsulfonalkyl; or the heteroaryl or aryl groups are optionally substituted with two substituents that form, together with the atoms to which they are attached, a 5 or 6 membered aryl ring, a 5 or 6 membered heteroaryl ring, a 5 or 6 cycloalkyl ring 6 members or a 5- or 6-membered heterocyclyl ring; optionally substituted with one or more substituents selected from oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl) alkyl , alkyne, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonyl) (alkyl) amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalquilaminocarbonilo, alquilaminoalquilaminocarbonilo, dialquilaminoalquilaminocarbonilo, heterociclilalquilaminocarbonilo, (alkylaminoalkyl) (alkyl) aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl , alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl and alkylsulfonalkyl.

ARP180100778A 2017-03-30 2018-03-28 THIOCARBAMATE DERIVATIVES AS A2A INHIBITORS AND METHODS FOR USE IN CANCER TREATMENT AR111200A1 (en)

Priority Applications (31)

Application Number Priority Date Filing Date Title
RS20220794A RS63557B1 (en) 2017-03-30 2018-03-30 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
EP18716193.0A EP3601296B1 (en) 2017-03-30 2018-03-30 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
MX2019011743A MX2019011743A (en) 2017-03-30 2018-03-30 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers.
KR1020247005971A KR20240027885A (en) 2017-03-30 2018-03-30 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
IL300149A IL300149A (en) 2017-03-30 2018-03-30 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
CA3058260A CA3058260A1 (en) 2017-03-30 2018-03-30 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
PL18716193.0T PL3601296T3 (en) 2017-03-30 2018-03-30 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
CN202211658370.5A CN115991679A (en) 2017-03-30 2018-03-30 2-oxothiazole derivatives as A2A inhibitors and compounds for the treatment of cancer
AU2018246355A AU2018246355B2 (en) 2017-03-30 2018-03-30 2-oxo-thiazole derivatives as A2A inhibitors and compounds for use in the treatment of cancers
EP22165965.9A EP4112623A1 (en) 2017-03-30 2018-03-30 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
KR1020197031322A KR102640927B1 (en) 2017-03-30 2018-03-30 2-Oxo-thiazole derivatives as A2A inhibitors and compounds for use in cancer treatment
JP2020503355A JP7197558B2 (en) 2017-03-30 2018-03-30 2-oxo-thiazole derivatives as A2A inhibitors and compounds for use in the treatment of cancer
HUE18716193A HUE059990T2 (en) 2017-03-30 2018-03-30 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
HRP20221039TT HRP20221039T1 (en) 2017-03-30 2018-03-30 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
BR112019020421A BR112019020421A8 (en) 2017-03-30 2018-03-30 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCER
DK18716193.0T DK3601296T3 (en) 2017-03-30 2018-03-30 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCER
SI201830747T SI3601296T1 (en) 2017-03-30 2018-03-30 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
CN202211706953.0A CN115873022A (en) 2017-03-30 2018-03-30 2-oxothiazole derivatives as A2A inhibitors and compounds for the treatment of cancer
CN201880034926.9A CN110678472B (en) 2017-03-30 2018-03-30 2-oxothiazole derivatives as A2A inhibitors and compounds for the treatment of cancer
TW107111155A TWI801372B (en) 2017-03-30 2018-03-30 Thiocarbamate derivatives as a2a inhibitors and methods for use in the treatment of cancers
PCT/EP2018/058301 WO2018178338A1 (en) 2017-03-30 2018-03-30 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
ES18716193T ES2926158T3 (en) 2017-03-30 2018-03-30 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
TW112113401A TWI836960B (en) 2017-03-30 2018-03-30 Thiocarbamate derivatives as a2a inhibitors and methods for use in the treatment of cancers
RU2019134724A RU2822758C2 (en) 2017-03-30 2018-03-30 Compounds of formula (i) and formula (a), pharmaceutical composition, medicinal product, use and method of obtaining compounds of formula (i)
LTEPPCT/EP2018/058301T LT3601296T (en) 2017-03-30 2018-03-30 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
US16/354,022 US10995101B2 (en) 2017-03-30 2019-03-14 2-oxo-thiazole derivatives as A2A inhibitors and compounds for use in the treatment of cancers
IL269710A IL269710B2 (en) 2017-03-30 2019-09-26 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
MX2022005298A MX2022005298A (en) 2017-03-30 2019-09-30 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers.
US16/993,897 US20210198281A1 (en) 2017-03-30 2020-08-14 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
US17/949,595 US20230159564A1 (en) 2017-03-30 2022-09-21 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers
JP2022199962A JP2023027282A (en) 2017-03-30 2022-12-15 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in treatment of cancers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17163781 2017-03-30

Publications (1)

Publication Number Publication Date
AR111200A1 true AR111200A1 (en) 2019-06-12

Family

ID=58461153

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100778A AR111200A1 (en) 2017-03-30 2018-03-28 THIOCARBAMATE DERIVATIVES AS A2A INHIBITORS AND METHODS FOR USE IN CANCER TREATMENT

Country Status (1)

Country Link
AR (1) AR111200A1 (en)

Similar Documents

Publication Publication Date Title
AR126406A2 (en) TETRAZOLINONE COMPOUNDS AND THEIR USE
AR104176A1 (en) IDO INHIBITORS (INDOLAMINE-2,3-DIOXYGENASE)
AR110922A1 (en) HIV INHIBITING COMPOUNDS
AR109805A1 (en) MICROBIOCIDES OXADIAZOL DERIVATIVES
AR101229A1 (en) IRAK4 INHIBITING AGENTS
CR20160548A (en) New Pirazolo Pyrimidine Derivatives and their Use as MALT1 Inhibitors
AR088175A1 (en) 3-PIRIMIDIN-4-IL-OXAZOLIDIN-2-USEFUL WAVES TO TREAT CANCER AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PH12016501047A1 (en) Ester derivatives of androgen receptor modulators and methods for their use
AR101986A1 (en) INHIBITORS OF HISTONE ACETILTRANSPHERASES SPIROCYCLES (HAT) AND METHODS FOR USE
AR099495A1 (en) AMIDA DERIVATIVES, OREXINE ANTAGONISTS
AR100810A1 (en) 3-QUINASA PHOSFATIDYLINOSITOL INHIBITORS
AR100806A1 (en) 3-QUINASA PHOSFATIDYLINOSITOL INHIBITORS
ES2669189T3 (en) Carbazole compounds useful as bromodomain inhibitors
AR100807A1 (en) 3-QUINASA PHOSFATIDYLINOSITOL INHIBITORS
CN105358522A8 (en) Ester derivatives of androgen receptor modulators and methods for their use
AR101392A1 (en) COMPOUNDS OF 6,7-DIHYDROPIRAZOLO [1,5-A] PIRAZIN-4 (5H) -ONA AND ITS USE AS NEGATIVE ALOSTERIC MODULATORS OF mGluR2 RECEPTORS
PE20190376A1 (en) PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF CANCER
AR103742A1 (en) DERIVATIVES OF TRIFLUOROMETILPROPANAMIDA
AR091208A1 (en) PIPERIDINE DERIVATIVES
EA201791816A1 (en) KV1.3 INHIBITORS AND THEIR APPLICATION IN MEDICINE
AR096023A1 (en) FUNGICIDE AMIDAS
AR095929A1 (en) METHODS TO CONTROL NEONICOTINOID RESISTANT PESTS
AR115085A1 (en) 3-AMINO-2,4,6-TRIAZINE DERIVATIVES AS INHIBITORS OF BRUTON TYROSINE KINASE (Btk)
PE20171443A1 (en) CARBOXAMIDE DERIVATIVES
AR096423A1 (en) COMPOUNDS OF 3,4-DIHIDRO-2H-ISOQUINOLIN-1-ONA AND 2,3-DIHIDRO-ISOINDOL-1-ONA